Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Desogestrel (Org-2969, Desogen; Org2969, Desogestrelum, Org 2969, Cerazette) is an approved synthetic progestin derivative used in female birth control pills as an oral contraceptive. Additionally, it has been applied to women's menopausal symptoms. When combined with an estrogen, desogestrel can be used as the progestogenic ingredient in oral contraceptive agents.
ln Vivo |
Desogestrel is extensively metabolized in rats and dogs following oral administration; in rats, desogestrel is primarily metabolized at the C3, C5, C11, and C15 positions. Desogestrel's 15α-position is modified by adding a hydroxy group, which is then conjugated with glucuronic acid. Dogs metabolize desogestrel primarily at the C3 and C17 positions[1].
|
---|---|
Animal Protocol |
Female Wistar rats, Female beagle dogs
56 μg/kg, 106 mg/kg (Rats); 67 μg/kg, 9.6 mg/kg(Dogs) oral administration |
References |
Molecular Formula |
C22H30O
|
---|---|
Molecular Weight |
310.47
|
Exact Mass |
310.22967
|
Elemental Analysis |
C, 85.11; H, 9.74; O, 5.15
|
CAS # |
54024-22-5
|
Related CAS # |
54024-22-5
|
Appearance |
Solid powder
|
SMILES |
CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34
|
InChi Key |
RPLCPCMSCLEKRS-BPIQYHPVSA-N
|
InChi Code |
InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
|
Chemical Name |
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
|
Synonyms |
Cerazette; DESOGESTREL; Desogen; Org-2969; Desogestrelum
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 16.7~62 mg/mL (53.7~199.7 mM)
Ethanol: ~62 mg/mL (~199.7 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2209 mL | 16.1046 mL | 32.2092 mL | |
5 mM | 0.6442 mL | 3.2209 mL | 6.4418 mL | |
10 mM | 0.3221 mL | 1.6105 mL | 3.2209 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03895099 | Active Recruiting |
Drug: Desogestrel luteal phase Drug: Desogestrel ovulatory phase |
Infertility | Centre Hospitalier Intercommunal Creteil |
September 4, 2020 | Phase 3 |
NCT04941833 | Completed | Drug: Desogestrel Oral Tablet | Endometrioma | Rajavithi Hospital | June 1, 2021 | Phase 2 Phase 3 |
NCT01559480 | Recruiting | Drug: Desogestrel Drug: Placebo |
Endometriosis | Mahidol University | January 2012 | Not Applicable |
NCT04422028 | Completed | Drug: Desogestrel 0.075 MG | Bioequivalence | Laboratorios Andromaco S.A. | September 16, 2020 | Phase 1 |
NCT01243697 | Completed | Drug: desogestrel | Ondine Syndrome | Assistance Publique - Hôpitaux de Paris |
April 2011 | Phase 2 Phase 3 |